Physician profile
Yujing Li
NPI 1922079698
$6,563.99
in general payments reported to CMS, 2019-2025
29 companies · $2,365 in 2025
The $2,365 reported for 2025 was more than what 97% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $932 · 2021: $902 · 2022: $764 · 2023: $669 · 2024: $379 · 2025: $2,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,675 · Travel and Lodging: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,675.47 |
| Travel and Lodging | $737.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,690.44 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,008.51 | 2019-2023 | Xarelto |
| Abbott Laboratories | $763.99 | 2019-2025 | Jot Dx, Aveir, Assurity |
| Amgen INC. | $459.02 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $325.97 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $322.81 | 2019-2025 | Bodyguardian |
| Galderma Laboratories, L.P. | $317.03 | 2021-2025 | |
| Amarin Pharma, INC. | $254.95 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.48 | 2021-2024 | Jardiance |
| Revance Therapeutics, INC. | $165.45 | 2024-2025 | Daxi, Daxxify |
| Cleerly, INC. | $130.76 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Medtronic, INC. | $111.95 | 2022-2025 | Micra, Tyrx |
| Arbor Pharmaceuticals, INC. | $111.40 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $102.98 | 2019 | |
| Azurity Pharmaceuticals, INC. | $86.14 | 2023-2025 | Edarbi, Edarbyclor, Edarbi |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $76.99 | 2022 | |
| Lilly USA, LLC | $73.32 | 2020-2021 | |
| Scpharmaceuticals INC. | $67.70 | 2025 | |
| Merck Sharp & Dohme LLC | $64.17 | 2022-2025 | Verquvo |
| Novo Nordisk INC | $39.87 | 2020 | |
| Impulse Dynamics (USA) INC. | $39.55 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $31.17 | 2024 | |
| Edwards Lifesciences Corporation | $29.88 | 2022 | |
| Alnylam Pharmaceuticals INC. | $26.07 | 2022 | |
| Altathera Pharmaceuticals LLC | $22.73 | 2023 | Sotalol Hydrochloride |
| Pfizer INC. | $20.95 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $20.74 | 2023 | Livalo, Seglentis |
| Allergan, INC. | $14.12 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $13.85 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yujing Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.